Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - Oncotelic Therapeutics, Inc. | b84100exv31w1.htm |
| EX-31.2 - EX-31.2 - Oncotelic Therapeutics, Inc. | b84100exv31w2.htm |
| EX-23.1 - EX-23.1 - Oncotelic Therapeutics, Inc. | b84100exv23w1.htm |
| 10-K - FORM 10-K - Oncotelic Therapeutics, Inc. | b84100e10vk.htm |
Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section
1350, chapter 63 of title 18, United States Code), each of the undersigned officers of OXiGENE,
Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge,
that:
The Annual Report for the year ended December 31, 2010 (the “Form 10-K”) of the Company fully
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934,
and the information contained in the Form 10-K fairly presents, in all material respects, the
financial condition and results of operations of the Company.
| Dated: March 16, 2011 | /s/ Peter J. Langecker | |||
| Peter J. Langecker, Chief Executive Officer | ||||
| Dated: March 16, 2011 | /s/ James B. Murphy | |||
| James B. Murphy, Chief Financial Officer | ||||